TipRanks on MSN

Incyte announces FDA granted breakthrough therapy designation to INCA033989

Incyte (INCY) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation to INCA033989, a ...

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S.
PharmiWeb

Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity

Data to be Presented During an Oral Platform Presentation at the American Epilepsy Society Annual MeetingSAN DIEGO--(BUSINESS ...

Order of cancer-driving mutations affects the chance of tumor development, study shows

The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, ...
EurekAlert!

Single enzyme failure found to drive neuron loss in dementia

Researchers at Helmholtz Munich, the Technical University of Munich and the LMU University Hospital Munich uncovered a mechanism that protects nerve cells from premature cell death, known as ...